Synthes-Stratec buys spinal gel company Gelifex:
This article was originally published in Clinica
Synthes-Stratec's US business has acquired a company that is developing hydrogels to treat degenerative disc disease. Gelifex, founded in 2002 by two professors at Drexel University in Philadelphia, Pennsylvania, is one of many seeking to commercialise alternatives to spinal fusion. Its technology is designed for implantation or injection into the space between vertebrae to restore motion and alleviate pain. A three-year Gelifex research project will continue at Drexel University at Synthes's expense. Gelifex was founded by Professors Tony Lowman of Drexel's chemical engineering department and Michele Marcolongo of materials science and engineering.